PolymarketVerfügbarkeit prüfenKein KYC2% GebührVerifizierte AuflösungsdatenGut kalibriertAktuelle implizite Wahrscheinlichkeit
Nein 94.1%
Marktqualitat
67 / 100
Mittlere Qualität24h-Volumen
14,5 €
Liquidität
31.421 €
Hohe LiquiditätGeld / Brief
5.0% / 6.0%
Spread
1.0 pt
Enger SpreadKommentare
7
Marktdaten
Aktualisiert vor 2 Minuten
4. Mai 26, 14:41 UTC1. Jan. 27, 04:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
Will a Hantavirus Vaccine be created in 2026? [Polymarket]
Manifold MarketsHantavirus pandemic in 2026?
PolymarketWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiHantavirus pandemic in 2026?
Manifold MarketsHantavirus pandemic in 2026? [Polymarket]
Manifold MarketsWill the CDC weaken vaccine recommendation against _____ for children and adolescents in 2026?
FutuurRegeln
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Offene Märkte
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.2pt97%
- Yes+0.2pt3%
- Gesamtvolumen
- 15,6 Mio. €
- 24h-Volumen
- 30.387,4 €
POLYMARKETEbola pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Gesamtvolumen
- 652.807,7 €
- 24h-Volumen
- 3547,3 €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No97%
- Yes-0.7pt3%
- Gesamtvolumen
- 1,6 Mio. €
- 24h-Volumen
- 2906,5 €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000+1.0pt97%
- Above 600059%
+2 weitere Ergebnisse
- Gesamtvolumen
- 865.320,4 €
- 24h-Volumen
- 2719,4 €
POLYMARKETNew pandemic in 2026?
- No+1.0pt94.1%
- Yes-1.0pt5.9%
- Gesamtvolumen
- 915.253 €
- 24h-Volumen
- 1382,5 €
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+1.0pt65%
- September41%
- June28%
- Gesamtvolumen
- 84.047,3 €
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will 3 mg THC beverages be federally legal to sell?
- Cyclosporiasis cases reported in the US in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Measles cases in U.S. in 2026?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
Häufige Fragen
- Wie stehen die aktuellen Quoten für Hantavirus vaccine in 2026??
- Polymarket bewertet No mit 94% (Stand: 9. September 2026).
- Wann wird Hantavirus vaccine in 2026? entschieden?
- Hantavirus vaccine in 2026? soll am 1. Januar 2027 entschieden werden.
- Wie wird Hantavirus vaccine in 2026? abgerechnet?
- Polymarket rechnet diesen Markt wie folgt ab: This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET.